Cell Reports Medicine最新文献

{"title":"A structural haplotype in the 17q21.31 MAPT region is associated with increased risk for chronic traumatic encephalopathy endophenotypes.","authors":"Xudong Han, Yichi Zhang, Jillian N Petrosky, Sarah Bald, Richard M Sherva, Adam Labadorf, Jonathan D Cherry, Jaeyoon Chung, Kurt Farrell, Bobak Abdolmohammadi, Shruti Durape, Brett M Martin, Joseph N Palmisano, John J Farrell, Victor E Alvarez, Bertrand R Huber, Brigid Dwyer, Daniel H Daneshvar, Kristen Dams-O'Connor, Gyungah R Jun, Kathryn L Lunetta, Lee E Goldstein, Douglas I Katz, Robert C Cantu, Martha E Shenton, Jeffrey L Cummings, Eric M Reiman, Robert A Stern, Michael L Alosco, Yorghos Tripodis, Lindsay A Farrer, Thor D Stein, John F Crary, Ann C McKee, Jesse Mez","doi":"10.1016/j.xcrm.2025.102084","DOIUrl":"https://doi.org/10.1016/j.xcrm.2025.102084","url":null,"abstract":"<p><p>Chronic traumatic encephalopathy (CTE) is a neurodegenerative tauopathy associated with repetitive head impact (RHI) exposure. Genetic variation in the 17q21.31 region, containing microtubule-associated protein tau (MAPT), has been implicated in tauopathies but has not been investigated in CTE. The region includes a megabase-long inversion (H1/H2) and copy-number variations, including α, β, and γ segments, which can be characterized as nine segregating structural haplotypes. We leveraged array SNP data and a reference panel across the 17q21.31 region to impute structural haplotypes and test their association with CTE endophenotypes in 447 European ancestry brain donors with RHI exposure. The H1β1γ1 haplotype was significantly associated with dementia and semi-quantitative tau burden in multiple cortical and medial temporal regions commonly affected in CTE. H1β1γ1 differential expression analyses in dorsolateral frontal cortex implicated cis-acting genes and inflammatory pathways. Taken together, the H1β1γ1 haplotype may help explain CTE heterogeneity among those with similar RHI exposure.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102084"},"PeriodicalIF":11.7,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tailoring an intravenously injectable oncolytic virus for augmenting radiotherapy.","authors":"Chen Xu, Liting Chen, Guangna Liu, Jiaqi Xu, Wei Lv, Xiaoyu Gao, Peijun Xu, Ming Tang, Yaohe Wang, Xiao Zhao, Guangjun Nie, Keman Cheng, Funan Liu","doi":"10.1016/j.xcrm.2025.102078","DOIUrl":"https://doi.org/10.1016/j.xcrm.2025.102078","url":null,"abstract":"<p><p>Oncolytic viruses (OVs) combined with radiotherapy (RT) show promise but are limited by challenges such as poor intravenous delivery and insufficient RT-induced DNA damage. In this study, an oncolytic adenovirus (AD) formulation, RadioOnco (AD@PSSP), is developed to improve delivery, infectivity, immune response, and RT efficacy. The multifunctional polyethylenimine (PEI)-selenium-polyethylene glycol (PEG) (PSSP) enhances intravenous delivery, shields the virus from rapid clearance, and enables targeted delivery to tumor sites after RT. The exposed PEI enhances the infectivity of AD through electrostatic interactions, thereby increasing DNA damage after RT by inhibiting the expression of DNA repair proteins, such as CHEK1 and CDK1. Furthermore, AD-PEI captures and delivers RT-induced tumor-released antigens to lymph nodes, activating robust anti-tumor immune responses. Animal model data demonstrate that RadioOnco overcomes RT resistance, targets distant metastases, and promotes long-term immunity, addressing metastasis and recurrence. In summary, this intravenously injectable OV enhances RT synergy through surface modification with multifunctional materials.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102078"},"PeriodicalIF":11.7,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Co-targeting BMI1 and MYC to eliminate cancer stem cells in squamous cell carcinoma.","authors":"Zhen Qin, Shuo Liu, Yunfei Zheng, Yujia Wang, Yiwen Chen, Xin Peng, Lingfei Jia","doi":"10.1016/j.xcrm.2025.102077","DOIUrl":"https://doi.org/10.1016/j.xcrm.2025.102077","url":null,"abstract":"<p><p>Bmi1⁺ tumor cells act as cancer stem cells (CSCs) driving relapse and therapy resistance in head and neck squamous cell carcinoma (HNSCC). Although BMI1 inhibitors reduce CSCs, combined cisplatin treatment targeting non-stem tumor cells is more effective in eliminating CSCs. Non-stem tumor cells may revert to CSCs post-treatment. However, in vivo evidence and underlying mechanisms remain unclear. Here, we demonstrate that BMI1 inhibitors induce temporary tumor regression followed by relapse. Lineage tracing reveals that keratin 16-marked non-stem tumor cells revert to Bmi1⁺ CSCs, which drive compensatory tumor growth after BMI1 targeting therapy. Mechanistically, BMI1 inhibitors activate DNA damage/nuclear factor κB (NF-κB) signaling and inflammatory cytokine secretion, subsequently stimulating myelocytomatosis viral oncogene homolog (MYC) expression in non-stem tumor cells to promote the reversion process. Genetic and pharmacological inhibition of MYC synergizes with BMI1 targeting, achieving sustained CSC eradication and relapse prevention. These findings provide insights into CSCs' plasticity and suggest dual BMI1/MYC blockade as an effective HNSCC treatment strategy.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102077"},"PeriodicalIF":11.7,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer.","authors":"Shumei Chia, Justine Jia Wen Seow, Rafael Peres da Silva, Chayaporn Suphavilai, Niranjan Shirgaonkar, Maki Murata-Hori, Xiaoqian Zhang, Elena Yaqing Yong, Jiajia Pan, Matan Thangavelu Thangavelu, Giridharan Periyasamy, Aixin Yap, Padmaja Anand, Daniel Muliaditan, Yun Shen Chan, Wang Siyu, Chua Wei Yong, Nguyen Hong, Gao Ran, Ngak Leng Sim, Yu Amanda Guo, Andrea Xin Yi Teh, Clarinda Chua Wei Ling, Emile Kwong Wei Tan, Fu Wan Pei Cherylin, Meihuan Chang, Shuting Han, Isaac Seow-En, Lionel Raphael Chen Hui, Anna Hwee Hsia Gan, Choon Kong Yap, Huck Hui Ng, Anders Jacobsen Skanderup, Vitoon Chinswangwatanakul, Woramin Riansuwan, Atthaphorn Trakarnsanga, Manop Pithukpakorn, Pariyada Tanjak, Amphun Chaiboonchoe, Daye Park, Dong Keon Kim, Narayanan Gopalakrishna Iyer, Petros Tsantoulis, Sabine Tejpar, Jung Eun Kim, Tae Il Kim, Somponnat Sampattavanich, Iain Beehuat Tan, Niranjan Nagarajan, Ramanuj DasGupta","doi":"10.1016/j.xcrm.2025.102053","DOIUrl":"https://doi.org/10.1016/j.xcrm.2025.102053","url":null,"abstract":"<p><p>Application of machine learning (ML) on cancer-specific pharmacogenomic datasets shows immense promise for identifying predictive response biomarkers to enable personalized treatment. We introduce CAN-Scan, a precision oncology platform, which applies ML on next-generation pharmacogenomic datasets generated from a freeze-viable biobank of patient-derived primary cell lines (PDCs). These PDCs are screened against 84 Food and Drug Administration (FDA)-approved drugs at clinically relevant doses (C_max), focusing on colorectal cancer (CRC) as a model system. CAN-Scan uncovers prognostic biomarkers and alternative treatment strategies, particularly for patients unresponsive to first-line chemotherapy. Specifically, it identifies gene expression signatures linked to resistance against 5-fluorouracil (5-FU)-based drugs and a focal copy-number gain on chromosome 7q, harboring critical resistance-associated genes. CAN-Scan-derived response signatures accurately predict clinical outcomes across four independent, ethnically diverse CRC cohorts. Notably, drug-specific ML models reveal regorafenib and vemurafenib as alternative treatments for BRAF-expressing, 5-FU-insensitive CRC. Altogether, this approach demonstrates significant potential in improving biomarker discovery and guiding personalized treatments.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102053"},"PeriodicalIF":11.7,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143787999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microneedle delivery of CAR-M-like engineered macrophages alleviates intervertebral disc degeneration through enhanced efferocytosis capacity.","authors":"Xingyu Zhou, Dingchao Zhu, Di Wu, Gaocai Li, Huaizhen Liang, Weifeng Zhang, Yali Wu, Hanpeng Xu, Zhengdong Zhang, Bide Tong, Yu Song, Kun Wang, Xiaobo Feng, Jie Lei, Hongchuan Wang, Xiaoguang Zhang, Liang Ma, Yuhang Chen, Junyu Wei, Zixuan Ou, Shuchang Peng, Xinghuo Wu, Lei Tan, Bingjin Wang, Cao Yang","doi":"10.1016/j.xcrm.2025.102079","DOIUrl":"https://doi.org/10.1016/j.xcrm.2025.102079","url":null,"abstract":"<p><p>Macrophages eliminate apoptotic cells produced daily in the body through efferocytosis. Restricted clearance can cause inflammation-related diseases. In intervertebral discs (IVDs), apoptotic nucleus pulposus cells (NPCs) are difficult to effectively remove, and their accumulation can cause changes in the inflammatory microenvironment, disrupt IVD homeostasis, and lead to IVD degeneration (IDD). Here, we present chimeric antigen receptor-M-like engineered macrophages (CAR-eMs) with enhanced efferocytosis capacity for IDD treatment. Macrophages undergo phenotypic transformation and a reduction in phagocytic ability after phagocyting apoptotic NPCs, but their efferocytosis capacity recovers with upregulated brain-specific angiogenesis inhibitor 1 (BAI1) expression. We develop a CAR-eM system with enhanced BAI1 expression and an IVD circular microneedle (MN) delivery system that utilizes arrays of MNs to deliver CAR-eMs into the deep IVD layers, thereby clearing apoptotic NPCs, ameliorating the inflammatory microenvironment, and repairing damaged IVDs. Our study explores the therapeutic potential of CAR-eM efferocytosis for IDD treatment.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102079"},"PeriodicalIF":11.7,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Altered baseline immunological state and impaired immune response to SARS-CoV-2 mRNA vaccination in lung transplant recipients.","authors":"Mengyun Hu, Ana Paula B N Oliveira, Zhuoqing Fang, Yupeng Feng, Molly Miranda, Sangeeta Kowli, Prabhu S Arunachalam, Gowri Vasudevan, Harold Sai-Yin Hui, Alba Grifoni, Alessandro Sette, Matthew Litvack, Nadine Rouphael, Mehul S Suthar, Xuhuai Ji, Holden T Maecker, Thomas Hagan, Gundeep Dhillon, Mark R Nicolls, Bali Pulendran","doi":"10.1016/j.xcrm.2025.102050","DOIUrl":"https://doi.org/10.1016/j.xcrm.2025.102050","url":null,"abstract":"<p><p>The effectiveness of COVID-19 mRNA vaccines is diminished in organ transplant patients. Using a multi-omics approach, we investigate the immunological state of lung transplant (LTX) recipients at baseline and after SARS-CoV-2 mRNA vaccination compared to healthy controls (HCs). LTX patients exhibit a baseline immune profile resembling severe COVID-19 and sepsis, characterized by elevated pro-inflammatory cytokines (e.g., EN-RAGE [also known as S100A12], interleukin [IL]-6), reduced human leukocyte antigen (HLA)-DR expression on monocytes and dendritic cells, impaired cytokine production, and increased plasma microbial products. Single-cell RNA sequencing identifies an enriched monocyte cluster in LTX patients marked by high S100A family expression and reduced cytokine and antigen presentation genes. Post vaccination, LTX patients show diminished antibody, B cell, and T cell responses, along with blunted innate immune signatures. Integrative analysis links these altered baseline immunological features to impaired vaccine responses. These findings provide critical insights into the immunosuppressed condition of LTX recipients and their reduced vaccine-induced adaptive and innate immune responses.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102050"},"PeriodicalIF":11.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143787998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MetaGP: A generative foundation model integrating electronic health records and multimodal imaging for addressing unmet clinical needs.","authors":"Fei Liu, Hongyu Zhou, Kai Wang, Yunfang Yu, Yuanxu Gao, Zhuo Sun, Sian Liu, Shanshan Sun, Zixing Zou, Zhuomin Li, Bingzhou Li, Hanpei Miao, Yang Liu, Taiwa Hou, Manson Fok, Nivritti Gajanan Patil, Kanmin Xue, Ting Li, Eric Oermann, Yun Yin, Lian Duan, Jia Qu, Xiaoying Huang, Shengwei Jin, Kang Zhang","doi":"10.1016/j.xcrm.2025.102056","DOIUrl":"https://doi.org/10.1016/j.xcrm.2025.102056","url":null,"abstract":"<p><p>Artificial intelligence makes strides in specialized diagnostics but faces challenges in complex clinical scenarios, such as rare disease diagnosis and emergency condition identification. To address these limitations, we develop Meta General Practitioner (MetaGP), a 32-billion-parameter generative foundation model trained on extensive datasets, including over 8 million electronic health records, biomedical literature, and medical textbooks. MetaGP demonstrates robust diagnostic capabilities, achieving accuracy comparable to experienced clinicians. In rare disease cases, it achieves an average diagnostic score of 1.57, surpassing GPT-4's 0.93. For emergency conditions, it improves diagnostic accuracy for junior and mid-level clinicians by 53% and 46%, respectively. MetaGP also excels in generating medical imaging reports, producing high-quality outputs for chest X-rays and computed tomography, often rated comparable to or superior to physician-authored reports. These findings highlight MetaGP's potential to transform clinical decision-making across diverse medical contexts.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102056"},"PeriodicalIF":11.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143787922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut microbiota and metabolites are linked to disease progression in multiple sclerosis.","authors":"Luke A Schwerdtfeger, Federico Montini, Toby B Lanser, Millicent N Ekwudo, Jonathan Zurawski, Shahamat Tauhid, Bonnie I Glanz, Renxin Chu, Rohit Bakshi, Tanuja Chitnis, Laura M Cox, Howard L Weiner","doi":"10.1016/j.xcrm.2025.102055","DOIUrl":"https://doi.org/10.1016/j.xcrm.2025.102055","url":null,"abstract":"<p><p>Progressive multiple sclerosis (MS) is a neurological disease with limited understanding of the biology associated with transition from relapsing to progressive disease. Intestinal microbes and metabolites are altered in MS, but relation to disease progression is largely unknown. We investigate microbiota and metabolites in subjects with stable MS, those who worsened, and in those with relapsing MS who became progressive over 2 years. We find that Eubacterium hallii, Butyricoccaceae, Blautia, and other short-chain fatty-acid-producing microbes have beneficial associations with worsening of disability, 3T magnetic resonance imaging (MRI) measures, cognition, and quality of life, while Alistipes is detrimentally associated. Global metabolomics identified serum and stool metabolites that are altered in progressive MS and in relapsing subjects who transitioned to progressive disease. Most fecal metabolites associated with disease progression are decreased, suggesting a deficiency of protective factors in the gut. Using a unique MS cohort, our findings identify gut microbiome and metabolite pathways influencing progressive MS.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102055"},"PeriodicalIF":11.7,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143787921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.","authors":"Ruth Plummer, Mikael H Sodergren, Rose Hodgson, Bríd M Ryan, Nina Raulf, Joanna P Nicholls, Vikash Reebye, Jon Voutila, Laura Sinigaglia, Tim Meyer, David J Pinato, Debashis Sarker, Bristi Basu, Sarah Blagden, Natalie Cook, Thomas R Jeffrey Evans, Jeffrey Yachnin, Cheng E Chee, Daneng Li, Anthony El-Khoueiry, Maria Diab, Kai-Wen Huang, Madhava Pai, Duncan Spalding, Thomas Talbot, Marcus S Noel, Bridget Keenan, Devalingam Mahalingam, Min-Sun Song, Mélanie Grosso, Denis Arnaud, Aurelie Auguste, Dimitris Zacharoulis, Jan Storkholm, Iain McNeish, Robert Habib, John J Rossi, Nagy A Habib","doi":"10.1016/j.xcrm.2025.102041","DOIUrl":"https://doi.org/10.1016/j.xcrm.2025.102041","url":null,"abstract":"<p><p>Many patients with cancer do not benefit from currently approved immune checkpoint inhibitors (ICIs), suggesting that additional immunomodulation of the immunosuppressive tumor microenvironment (TME) is required. MTL-CCAAT enhancer-binding protein alpha (CEBPA) specifically upregulates the expression of the master myeloid transcription factor, CEBPA, relieving myeloid-driven immunosuppression. Here, we report the safety, tolerability, pharmacokinetics, and efficacy of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumors that typically show ICI resistance. Multimodal exploratory analyses of paired patient biopsies demonstrate biological changes associated with the combination treatment of MTL-CEBPA and pembrolizumab, including increased infiltration of T cell and antigen-presenting cells supporting conversion from an immune-desert toward a more immune-inflamed TME. Patients with disease stabilization demonstrate reductions in immunosuppressive myeloid cells post treatment. Collectively, these data support a role for MTL-CEBPA in reducing immunosuppression in the TME. This study was registered at ClinicalTrials.gov (NCT04105335).</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102041"},"PeriodicalIF":11.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Common and specific effects in brain oscillations and motor symptoms of tDCS and tACS in Parkinson's disease.","authors":"Jiafang Liu, Ying Zhu, Biao Chen, Qiujian Meng, Panpan Hu, Xianwen Chen, Junjie Bu","doi":"10.1016/j.xcrm.2025.102044","DOIUrl":"https://doi.org/10.1016/j.xcrm.2025.102044","url":null,"abstract":"<p><p>Parkinson's disease (PD) leads to neurodegeneration and abnormal brain oscillations, causing motor dysfunction. Transcranial stimulation (transcranial direct current stimulation [tDCS]/transcranial alternating current stimulation [tACS]) may alleviate symptoms, but their oscillatory modulation mechanisms remain unclear. This randomized controlled trial (RCT) examines the effects of single-session tDCS/tACS on 60 PD patients, assigned to tDCS, tACS (20 Hz), or sham groups. Each receives 20-min left motor cortex stimulation while performing a simple reaction task. Open-source resting-state electroencephalogram (EEG) data reveal increased theta and decreased beta power in PD. In the RCT, tDCS and tACS enhance beta power, improving rigidity and bradykinesia. Additionally, tDCS reduces theta power, specifically alleviating tremor symptoms. Notably, the theta/beta ratio predicts and mediates tremor changes induced by tDCS more effectively than theta power alone. This sutdy revealed that tDCS broadly modulates oscillations, improving multiple symptoms, while tACS targets a single oscillation for specific symptom relief, emphasizing the crucial role of diverse oscillations in PD motor pathophysiology. This study was registered at ClinicalTrials.gov (NCT05678725).</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102044"},"PeriodicalIF":11.7,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}